News & Insights

India's Cadila gets regulatory nod to repurpose Hepatitis C drug for COVID-19

April 23, 2021 — 05:22 am EDT

Written by Sachin Ravikumar for Reuters ->

BENGALURU, April 23 (Reuters) - India's Cadila Healthcare Ltd CADI.NS received approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19, the drugmaker said on Friday.

(Reporting by Sachin Ravikumar in Bengaluru)

((saisachin.r@tr.com; +91 80 6182 2754; Twitter: @sachinr27))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Reuters
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.
More articles by this source ->

More Related Articles

Info icon

This data feed is not available at this time.

  • •

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.